Article and Video CATEGORIES
The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology. Here's my discussion of some of the highlights of this work and what this means.
[powerpress]
I'm hoping we'll have more information to update everyone on the developments in the story of MEK inhibitors for KRAS mutation-positive NSCLC, and perhaps also a broader population of patients with NSCLC, in the next year or two.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…